Cargando…
Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2
Hydroxychloroquine, used to treat malaria and some autoimmune disorders, potently inhibits viral infection of SARS coronavirus (SARS-CoV-1) and SARS-CoV-2 in cell-culture studies. However, human clinical trials of hydroxychloroquine failed to establish its usefulness as treatment for COVID-19. This...
Autores principales: | Ou, Tianling, Mou, Huihui, Zhang, Lizhou, Ojha, Amrita, Choe, Hyeryun, Farzan, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845965/ https://www.ncbi.nlm.nih.gov/pubmed/33465165 http://dx.doi.org/10.1371/journal.ppat.1009212 |
Ejemplares similares
-
The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity
por: Zhang, Lizhou, et al.
Publicado: (2020) -
Cytoplasmic Tail Truncation Stabilizes S1-S2 Association and Enhances S Protein Incorporation into SARS-CoV-2 Pseudovirions
por: Zhang, Lizhou, et al.
Publicado: (2023) -
Mechanisms of SARS-CoV-2 entry into cells
por: Jackson, Cody B., et al.
Publicado: (2021) -
An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines
por: Quinlan, Brian D., et al.
Publicado: (2020) -
An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
por: Guo, Yan, et al.
Publicado: (2021)